Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells

International Journal of Medical Sciences

Volumn 9, Issue 10, 2012, Pages 881-893

  Lee, Young Ju ^a   Won, A Jin ^a   Lee, Jaewon ^a   Jung, Jee H ^a   Yoon, Sungpil ^b   Lee, Byung Mu ^c   Kim, Hyung Sik ^a  

^a Pusan National University   (South Korea)

^b National Cancer Center   (South Korea)

^c Sungkyunkwan University   (South Korea)

Author keywords

Apoptosis; Autophagy; Breast cancer; HDAC inhibitor; Tamoxifen resistant

Indexed keywords

AFIMOXIFENE; BECLIN 1; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 7; HISTONE H3; HISTONE H4; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; WESTERN BLOTTING;

APOPTOSIS; AUTOPHAGY.; BREAST CANCER; HDAC INHIBITOR; TAMOXIFEN-RESISTANT;

ANIMALS; APOPTOSIS; AUTOPHAGY; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MCF-7 CELLS; MICE; TAMOXIFEN; TRANSPLANTATION, HETEROLOGOUS;

EID: 84869005194     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.5011     Document Type: Article

References (46)

1. [Internet] International Agency for Research on Cancer (IARC). World Cancer Report 2008. http://globocan.iarc.fr/factsheets/populations/ factsheet.asp?uno=900.
2. McGuire WL, Horwitz KB, Pearson OH, et al. Current status of estrogen and progesterone receptors in breast cancer. Cancer 1977; 39: 2934-47.
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;365: 1687-717.
4. The BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009;361: 766-76.
5. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004;11: 643-58.
6. Aguilar H, Solé X, Bonifaci N et al. Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. Oncogene 2010;29: 6071-83.
7. Yue W, Fan P, Wang J, et al. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol 2007;106: 102-10.
8. Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO Study. J Clin Oncol 2012;30: 2718-24.
9. Munster PN, Thurn KT, Thomas S, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 2011;104: 1828-35.
10. Esteve JM, Knecht E. Mechanisms of autophagy and apoptosis: Recent developments in breast cancer cells. World J Biol Chem 2011;26: 232-8.
11. Cook KL, Shajahan AN, Clarke R. Autophagy and endocrine resistance in breast cancer. Expert Rev Anticancer Ther 2011;11: 1283-94.
12. Notte A, Leclere L, Michiels C. Autophagy as a mediator of chemotherapy- induced cell death in cancer. Biochem Pharmacol 2011;82: 427-34.
13. Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol 2010;221: 3-12.
14. Park JH, Ahn MY, Kim TH, et al. A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen- resistant MCF-7 breast cancer cells. Invest New Drugs 2012;30:1887-98.
15. Ahn MY, Ahn SG, Yoon JH. Apicidin, a histone deaceylase inhibitor, induces both apoptosis and autophagy in human oral squamous carcinoma cells. Oral Oncol 2011;47:1032-38.
16. Shao Y, Gao Z, Marks PA, et al. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2004;101: 18030-35.
17. Carew JS, Nawrocki ST, Kahue CN, et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 2007;110: 313-22.
18. Chavan AV, Somani RR. HDAC inhibitors: new generation of target specific treatment. Mini Rev Med Chem. 2010;10: 1263-76.
19. Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009;107: 600-8.
20. Marks PA, Richon VM, Breslow R, et al. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001;13: 477-83.
21. Schaefer EW, Loaiza-Bonilla A, Juckett M, et al. Phase II Consortium. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica 2009;94: 1375-82.
22. Mutze K, Langer R, Becker K, et al. Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer. Ann Surg Oncol 2010;17: 3336-43.
23. Paglin S, Hollister T, Delohery T, et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 2001;61: 439-44.
24. Phuong NT, Kim SK, Lim SC, et al. Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells. Breast Cancer Res Treat 2011;130: 73-83.
25. De Duve C, de Barsy T, Poole B, et al. Commentary. Lysosomotropic agents. Biochem Pharmacol 1974;23: 2495-531.
26. Muss HB. Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat 1992;21: 15-26.
27. Castro-Galache MD, Ferraqut JA, Barbera VM, et al. Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors. Int J Cancer 2003;104: 579-86.
28. Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429: 457-63.
29. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4: 143-53.
30. Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev 2004;18: 2315-35.
31. Mai A, Massa S, Rotili D, et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 2005;25: 261-309.
32. Lee JH, Choy ML, Ngo L, et al. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci US A. 2010;107: 14639-44.
33. Lee JH, Choy ML, Ngo L, et al. Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2011;108: 19629-34.
34. Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J Med Chem 2003;46: 5097-116.
35. Hrzenjak A, Kremser M-L, Strohmeier B, et al. SAHA induces caspase- independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR path-way. J Pathol 2008;216: 495-504.
36. Dietrich CS, Greenberg VL, Desimone CP, et al. Suberoylanilide hydroxamic acid (SAHA) protentiates paclitaxel-induced apoptosis in ovarian cancer cell lines. Gynecol Oncol 2010;116: 126-30.
37. Long J, Zhao J, Yan Z, et al. Antitumor effects of a novel sulfur- containing hydroxamate histone deacetylase inhibitor H40. Int J Cancer 2009;124: 1235-44.
38. Ahn MY, Lee J, Na YJ, et al. Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells. Chem Biol Interact 2009;179: 169-77.
39. Marks PA, Richon VM, Miller T, et al. Histone deacetylase inhibitors. Adv Cancer Res 2004;91: 137-68
40. Kim DH, Kim M, Kwon HJ. Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J Biochem Mol Biol 2003;36: 110-19
41. Kim JS, Lee S, Lee T, et al. Transcriptional activation of p21(WAF1/CIP1) by apicidin, a novel histone deacetylase inhibitor. Biochem Biophys Res Commun 2001;281: 866-71
42. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6: 38-51.
43. Carew JS, Nawrocki ST, Kahue CN, et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 2007;110: 313-22.
44. Oh M, Choi IK, Kwon HJ. Inhibition of histone deacetylase1 induces autophagy. Biochem Biophys Res Commun 2008;369: 1179-83.
45. Yamamoto S, Tanaka K, Sakimura R, et al. Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. Anticancer Res 2008;28: 1585-91.
46. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008;132: 27-42.